M.B.X. Biosciences
Develops precision peptide therapies for endocrine and metabolic disorders.
$63.00
After-hours close+0.01 (+0.02%)
At close$62.99(−5.12%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 110.38%Insiders 13.91%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 47.60M · Float 20.70M · 43.5% free float
Institutions13F, as of Mar 31, 2026
161 holders · 52.54M shares · 38 new positions · 81 increased · 48 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6.65M | 13.98% | 0 | May 15, 2026 |
| Orbimed Advisors LLC | 3.64M | 7.64% | −297.3K | May 15, 2026 |
| Nea Management Company, LLC | 3.61M | 7.59% | 0 | May 15, 2026 |
| Wellington Management Group LLP | 3.19M | 6.71% | −158.1K | May 15, 2026 |
| BlackRock, Inc. | 2.94M | 6.18% | +21.7K | May 13, 2026 |
| FMR LLC | 2.94M | 6.17% | +2.92M | May 15, 2026 |
| Deep Track Capital, LP | 2.76M | 5.79% | −492.2K | May 15, 2026 |
| NVP Associates, LLC | 2.14M | 4.49% | 0 | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Patrick J. Heronincl. Fhmls Xi, L.L.C., Fhmls X, L.L.C. +8 more | 11.70% | 5.24M | 13D | Aug 10, 2026 ↗ |
| Edward T. Mathersincl. New Enterprise Associates 17, L.P., Ali Behbahani +9 more | 8.10% | 3.62M | 13D | Nov 10, 2025 ↗ |
| Wellington Management Group LLP | 7.50% | 3.35M | 13G | Feb 10, 2026 ↗ |
| Deep Track Capital, LP | 6.55% | 2.19M | 13G | Aug 14, 2025 ↗ |
| Orbimed Advisors LLCincl. Orbimed Genesis GP LLC, Orbimed Capital GP Vii LLC | 6.40% | 3.07M | 13D | Aug 10, 2026 ↗ |
| FMR LLC | 6.20% | 2.94M | 13G | May 6, 2026 ↗ |
| BlackRock, Inc. | 5.50% | 2.63M | 13G | Jul 29, 2026 ↗ |
| Paradigm BioCapital Advisors LP | 5.20% | 2.49M | 13G | Jun 24, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Patrick J. Heron | director, 10 percent owner: | 5.22M | 10.97% | Sep 30, 2025 |
| P. Kent Hawryluk | director, officer: President & CEO | 1.21M | 2.55% | May 8, 2026 |
| Steven L. Hoerter | director, officer: President and CEO | 102.9K | 0.22% | Aug 4, 2026 |
| John W. Smither | officer: Chief Financial Officer | 28.0K | 0.06% | Aug 4, 2026 |
| Ora H. Pescovitz | director | 24.3K | 0.05% | Apr 10, 2025 |
| Richard Bartram | officer: Chief Financial Officer | 15.0K | 0.03% | Feb 3, 2026 |
| Salomon Azoulay | officer: Chief Medical Officer | 14.4K | 0.03% | Aug 5, 2026 |
3 ten-percent owners hold 6.34M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (4.01M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 4, 2026 | Salomon Azoulayofficer: Chief Medical Officer | Sale | 370 | $65.77 | 14,399 |
| May 8, 2026 | Salomon Azoulayofficer: Chief Medical Officer | Sale · 2 lots | 70,003 | $38.36 | 14,769 |
| May 6, 2026 | P. Kent Hawrylukdirector, officer: President & CEO | Sale | 607 | $29.54 | 727,667 |
| May 6, 2026 | Salomon Azoulayofficer: Chief Medical Officer | Sale | 231 | $29.54 | 14,769 |
| Mar 13, 2026 | P. Kent Hawrylukdirector, officer: President & CEO | Purchase | 18,500 | $28.41 | 486,777 |
| Oct 20, 2025 | P. Kent Hawrylukdirector, officer: President & CEO | Purchase | 20,000 | $13.64 | 468,277 |
| Oct 17, 2025 | Steven L. Hoerterdirector | Purchase | 20,000 | $13.25 | 20,000 |
| Sep 26, 2025 | Patrick J. Herondirector, 10 percent owner: | Purchase | 666,666 | $18.00 | 5,219,440 |
CongressHouse and Senate disclosures
Not reported.